A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs LGD 6972 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Ligand Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 09 May 2017 According to a Ligand Pharmaceuticals media release, enrollment has been completed during the 1Q 2017.
- 27 Feb 2017 According to a Ligand Pharmaceuticals media release, topline results are expected in September 2017.